This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

VETERANS ADMINISTRATION ADJUVANT CANCER CHEMOTHERAPY COOPERATIVE GROUP

AMA Arch Surg. 1963;86(6):926-931.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The fluorinated pyrimidines were first introduced as cancer chemotherapeutic drugs in 1957 by Heidelberger.³ The first of these, fluorouracil (FU), has received rather widespread usage and is now available on the market. Numerous other drugs in the group have been developed both by alterations of the pyrimidine structure and by using other members of the halogen family. Of these newer drugs, 5-fluorodeoxyuridine (FUDR) has shown the most promise and has been used most widely in clinical trials. Pharmacologic studies have shown that FUDR has about one half the toxicity of the parent FU; however, indications are that quantitatively it has only one half of the therapeutic effectiveness of the parent drug. In studies by Curreri and Ansfield¹ the therapeutic effectiveness of this group of drugs against carcinoma of the alimentary tract, especially carcinoma of the large bowel, was demonstrated. The studies also indicated that FUDR is more effective . . . [Full Text PDF of this Article]

Footnotes
Presented at the 70th Annual Session of the Western Surgical Association, St. Louis, Nov 29-Dec 1, 1962.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?